WHO Drug Information Vol. 19, No. 3, 2005
(2005; 72 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuPersonal Perspectives
Fermer ce répertoireSafety and Efficacy Issues
Afficher le documentTransdermal fentanyl: abuse by adolescents
Afficher le documentSafety of fentanyl transdermal patches
Afficher le documentRosiglitazone: decreased high-density lipoprotein cholesterol
Afficher le documentIbuprofen: Stevens-Johnson syndrome
Afficher le documentStringent conditions for COX-2 Inhibitors
Afficher le documentSildenafil, tadalafil and vardenafil: eye problems reported
Afficher le documentNesiritide: safety report and measures
Afficher le documentMifepristone, sepsis and blood infection
Afficher le documentMifepristone: revised safety information
Afficher le documentSuicidality with SSRIs in adults
Afficher le documentEzetimibe and muscle disorders
Afficher le documentPathological gambling with cabergoline
Afficher le documentIcodextrin peritoneal dialysis solution: falsely elevated blood glucose readings
Afficher le documentNew requirements for pseudoephedrine products
Afficher le documentEfalizumab: warning of thrombocytopenia
Afficher le documentAntiretrovirals: HIV, hepatic impairment and HBV/HCV
Ouvrir ce répertoire et afficher son contenuHerbal Medicines
Ouvrir ce répertoire et afficher son contenuRegulatory Action and News
Ouvrir ce répertoire et afficher son contenuEssential Medicines
Ouvrir ce répertoire et afficher son contenuAccess to Medicines
Ouvrir ce répertoire et afficher son contenuThe International Pharmacopoeia
Afficher le documentRecommended International Nonproprietary Names: List 54
 

New requirements for pseudoephedrine products

United States of America - Pharmacies that engage in over-the-counter sales of tablet forms of products containing ephedrine, pseudoephedrine, or norpseudoephedrine must keep those products behind the pharmacy counter, or in a locked case within 30 feet and in a direct line of sight from a pharmacy counter staffed by an employee of the pharmacy. This law does not apply to liquid, liquid capsule, or liquid-gel capsule forms of the products. There are also new record-keeping requirements when selling one of these products. Before completing the over-the-counter sale of a product containing ephedrine, pseudoephedrine, or norpseudoephedrine, a pharmacy must require the person making the purchase to:

• display a driver's license or other form of identification containing the person's photograph and indicating that the person is 16 years of age or older; and

• sign for the purchase.


The pharmacy must make a record of the sale including:

• the name of the person making the purchase; the date of the purchase; and
• the item and number of grams purchased.


The pharmacy must take actions necessary to prevent a person who makes over-the-counter purchases of one or more products containing ephedrine, pseudoephedrine, or norpseudoephedrine from obtaining more than two packages of those products in a single transaction; or six grams of ephedrine, pseudoephedrine, norpseudoephedrine, or a combination of those substances.

Reference: Texas State Board of Pharmacy, on http://www.tsbp.state.tx.us

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 19 janvier 2012